NCT00138541View on ClinicalTrials.gov

Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

vildagliptin

Trial Locations (1)

07936

Novartis Pharmaceuticals, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY